Pravastatin Sodium
Brand names: Pravastatin Sodium
Part of: Statins
At a glance
- Medicare prescriptions, 2024
- 8,700,849
- Medicare drug cost
- $117.6M
- Average cost per prescription
- $13.51
- Clinicians who prescribed it
- 171,140
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
Pravastatin sodium tablets are indicated: To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia. Hypertriglyceridemia.
From the FDA-approved prescribing information (label dated July 2026). Full labels on DailyMed (opens in a new tab)
Who prescribes it
- Family Medicine 36.1%
- Internal Medicine 29.5%
- Nurse Practitioners 16.1%
- Cardiology 5.4%
- Physician Assistants 5.2%
- Interventional Cardiology 1.7%
- Geriatric Medicine 1.3%
- General Practice 1.1%
- Endocrinology & Diabetes 0.8%
- Nephrology (Kidney) 0.4%
- Hospitalist 0.4%
- Infectious Disease 0.2%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions fell 21% from 2019 to 2024.
Biggest change by state since 2019
- North Dakota +0%
- District of Columbia −4%
- Utah −4%
- Maine −4%
- Idaho −8%
- Puerto Rico (smallest change) −40%
- Mississippi (smallest change) −30%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
What it looks like
Pills from 4 makers on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.
A-S Medication Solutions
| Strength | Looks like | Imprint |
|---|---|---|
| 40 mg | green round tablet, 10 mm | TEVA 7202 |
Aurobindo Pharma Limited
| Strength | Looks like | Imprint |
|---|---|---|
| 10 mg | yellow rectangle tablet, 6 mm | Y 37 |
| 20 mg | white rectangle tablet, 8 mm | T 36 |
| 40 mg | yellow rectangle tablet, 10 mm | Y 39 |
| 80 mg | yellow oval tablet, 17 mm | Y 38 |
Havix Group Inc D-B-A Aavis Pharmaceuticals
| Strength | Looks like | Imprint |
|---|---|---|
| 30 mg | brown round tablet, 10 mm | FL19 |
| 60 mg | brown round tablet, 17 mm | FL21 |
Northstar Rxllc
| Strength | Looks like | Imprint |
|---|---|---|
| 10 mg | yellow round tablet, 6 mm | G5 10 |
| 20 mg | yellow rectangle tablet, 8 mm | G5 20 |
| 40 mg | green rectangle tablet, 10 mm | G5 40 |
| 80 mg | yellow oval tablet, 18 mm | G5 80 |
Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.
Industry payments about this drug
No industry payments to clinicians named this drug in 2025.
Recalls and shortages
Not on the FDA drug shortage list.
3 recalls since 2020
- Mar 2025 · Glenmark Pharmaceuticals Inc., USA · Class II
CGMP Deviations - Jun 2024 · Glenmark Pharmaceuticals Inc., USA · Class II
Failed Dissolution Specifications: results below specifications - Feb 2023 · Accord Healthcare, Inc. · Class II
CGMP Deviations: recalling drug products following an FDA inspection.
Recalls usually affect specific lots from one maker, not every version of a drug. Class I is the most serious; most drug recalls are Class II. FDA recalls (opens in a new tab)
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.